Swedish biotech Camurus, known for developing long-acting treatments for chronic conditions, is reportedly in talks to buy US-based Braeburn Pharmaceuticals Inc. Since 2014, Camurus and Braeburn have collaborated on Brixadi, a long-acting buprenorphine injection known as Buvidal outside the US. That year, Camurus granted Braeburn exclusive US commercialisation rights in a deal worth $20 million upfront, with potential milestones reaching over $150 million. Just last week, Switzerland’s Novartis announced a $1.4 billion deal for New York–based Tourmaline Bio to bolster its immunology portfolio. For Camurus, a relatively smaller player, acquiring Braeburn would be a transformative leap, thrusting it deeper into the US market for long-acting opioid treatments.